Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of Clover Health Investments Corp (NASDAQ: CLOV) was $3.76 for the day, down -1.31% from the previous closing price of $3.81. In other words, the price has decreased by -$1.31 from its previous closing price. On the day, 5.75 million shares were traded. CLOV stock price reached its highest trading level at $3.859 during the session, while it also had its lowest trading level at $3.71.
Ratios:
Our analysis of CLOV’s different ratios will help us gain a deeper understanding of the company. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Craig Hallum on December 17, 2024, initiated with a Buy rating and assigned the stock a target price of $6.
On October 07, 2024, UBS started tracking the stock assigning a Neutral rating and target price of $4.
Cowen Upgraded its Underperform to Market Perform on February 02, 2022, whereas the target price for the stock was revised from $7 to $3.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 17 ’25 when Reynoso Jamie L. sold 16,514 shares for $2.69 per share. The transaction valued at 44,423 led to the insider holds 2,955,226 shares of the business.
JAMIE REYNOSO bought 16,514 shares of CLOV for $44,588 on Oct 17 ’25. On Oct 07 ’25, another insider, Reynoso Jamie L., who serves as the CEO, Medicare Advantage of the company, sold 2,012 shares for $2.65 each. As a result, the insider received 5,332 and left with 3,043,172 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLOV now has a Market Capitalization of 1927047168 and an Enterprise Value of 1725775232. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.20 while its Price-to-Book (P/B) ratio in mrq is 5.27. Its current Enterprise Value per Revenue stands at 1.073 whereas that against EBITDA is -42.03.
Stock Price History:
The Beta on a monthly basis for CLOV is 2.09, which has changed by -0.059259236 over the last 52 weeks, in comparison to a change of 0.18258524 over the same period for the S&P500. Over the past 52 weeks, CLOV has reached a high of $4.87, while it has fallen to a 52-week low of $2.12. The 50-Day Moving Average of the stock is 29.44%, while the 200-Day Moving Average is calculated to be 13.02%.
Shares Statistics:
CLOV traded an average of 8.92M shares per day over the past three months and 12777150 shares per day over the past ten days. A total of 390.25M shares are outstanding, with a floating share count of 385.60M. Insiders hold about 24.76% of the company’s shares, while institutions hold 28.75% stake in the company. Shares short for CLOV as of 1760486400 were 54071005 with a Short Ratio of 6.06, compared to 1757894400 on 49278776. Therefore, it implies a Short% of Shares Outstanding of 54071005 and a Short% of Float of 13.22.
Earnings Estimates
The dynamic stock of Clover Health Investments Corp (CLOV) is currently attracting attention from 1.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is $0.0, with high estimates of $0.0 and low estimates of $0.0.
Analysts are recommending an EPS of between $0.1 and $0.1 for the fiscal current year, implying an average EPS of $0.1. EPS for the following year is $0.14, with 1.0 analysts recommending between $0.14 and $0.14.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 3 analysts. It ranges from a high estimate of $475.4M to a low estimate of $467.95M. As of. The current estimate, Clover Health Investments Corp’s year-ago sales were $330.99MFor the next quarter, 3 analysts are estimating revenue of $476.9M. There is a high estimate of $486.6M for the next quarter, whereas the lowest estimate is $471.1M.
A total of 3 analysts have provided revenue estimates for CLOV’s current fiscal year. The highest revenue estimate was $1.9B, while the lowest revenue estimate was $1.88B, resulting in an average revenue estimate of $1.89B. In the same quarter a year ago, actual revenue was $1.37BBased on 3 analysts’ estimates, the company’s revenue will be $2.48B in the next fiscal year. The high estimate is $2.6B and the low estimate is $2.32B.
